tbuckley/cabot-search huggingface dataset:
AB0869 The Content of Adiponectin in The Blood of Children with Rheumatic Diseases
Authors: I. Chyzheuskaya, L. Belyaeva, R. Filonovich, H. Khrustaleva, L. Zajtseva, T. Yuraga
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The hormone adiponectin is an indispensable component in the regulation of energy homeostasis and maintaining optimal lipid profile. It was found that low levels of adiponectin may be regarded as a predictor of metabolic syndrome. Despite the fact that adiponectin has an effect on energy homeostasis and is an anti-inflammatory agent, its main role is antiatherogenic effect and influence on the lipid profile body. <h3>Objectives</h3> to study the contents of adiponectin in the blood of children with rheumatic diseases. <h3>Methods</h3> Indicators serum lipid spectrum (total cholesterol, triglycerides, and HDL cholesterol) were studied at a biochemical analyzer. The concentration of adiponectin and serum CRP levels determined by ELISA. Statistical analysis was performed using the software package Statistica 8.0 (“StatSoft, Inc.”, USA). <h3>Results</h3> The study involved 54 children with juvenile idiopathic arthritis (JIA), 18 children with systemic lupus erythematosus (SLE) and 24 children with juvenile scleroderma (JS). Most of the children receiving long-term glucocorticoid and immunosuppressive therapy. 28 children with JIA, 9 children with SLE and 11 children with JS were overweight. Obesity is defined in 13 children with JIA, 8 children with SLE and 5 children with JS. When comparing the average concentrations of adiponectin according to the body mass index (BMI) found that with an increase in this index decreased adiponectin content in blood. Adiponectin level was significantly lower in obese children (10,8±4,6 mg/ml) compared with children with overweight (13,2±5,3 mg/ml) and children with normal body weight (16,4±4,1 mg/ml). In healthy children adiponectin content was 21,3±5,7 mg/ml. There was a significant negative correlation of adiponectin with body mass index (r=-0,36), glucose concentrations (r=-0,29), C-reactive protein (r=-0,31), the levels of blood pressure (r=-0.34) and positive to the level of high density lipoprotein (r=0.26). <h3>Conclusions</h3> The negative correlation between the level of adiponectin blood concentration of C-reactive protein and a positive correlation with the level of HDL indicates the probable anti-inflammatory properties of adiponectin and its protective effect against the development of atherosclerosis in children with rheumatic diseases. <h3>Acknowledgement</h3> This study would not have been possible without the collaboration of numerous Belarusian pediatric rheumatologists, patients and their parents. <h3>Disclosure of Interest</h3> None declared
AB0672 Prevalence and Risk Factors of Osteoporosis and Low Bone Mineral Density in Patients with Ankylosing Spondylitis in Hong Kong: A Cross-Sectional Study
Authors: C.Y.S. Ho
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The disease process of ankylosing spondylitis (AS) is characterized by chronic inflammation. Osteoporosis is now known to be associated with chronic inflammation. Bone loss occurs early in AS increasing the risk of fracture, and is related mainly to the inflammatory process. This study aims to determine the relationship between AS and osteoporosis. <h3>Objectives</h3> To determine the prevalence and risk factors of low bone mineral density (BMD) in a local Hong Kong Chinese cohort of ankylosing spondylitis (AS) patients. Dual X-ray absortiometry (DXA) scan at different sites were compared and evaluated. <h3>Methods</h3> Ninety-two patients with AS were enrolled in this study. Clinical, demographic and radiological data were collected. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score (ASDAS), Patient and Physician global scores, Health Assessment Questionnaire (HAQ) and Bath AS Metrology Index (BASMI) were evaluated. BMD at the lumbar spine via antero-posterior (AP) and lateral projections, neck of femur (NOF) and total hip were measured. <h3>Results</h3> Low BMD was found in half of the 92 Chinese AS patients. Factors associated with low BMD were BASDAI, BASMI, post-menopausal status, body mass index (BMI), alcohol use and family history of AS. Multiple logistic regression analysis by backward selection revealed that BASDAI (odds ratio (OR) 1.03, 95% confidence interval (CI)1.00–1.06; <i>p</i> =0.031), post-menopausal status (OR 6.11, 95% CI 1.07–34.81; <i>p</i> =0.041), BMI (OR 0.81, 95% CI 0.71–0.93; <i>p</i> =0.003) and alcohol use (OR 4.79, 95% CI 1.49–15.38; <i>p</i> =0.008) were significantly associated with low BMD. Total hip BMD was more sensitive than AP lumbar BMD in detecting low BMD in AS. <h3>Conclusions</h3> Low BMD in AS is not uncommon and often underdiagnosed. BASDAI, post-menopausal status, alcohol use and BMI were independently associated with low BMD in this study. <h3>References</h3> El Magharaoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 2003;71:291–295 Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011;22:421–433 Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa T-P, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum dis 2009;68:1839–1842 Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, El Maghraoui. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009;44:772–776 <h3>Disclosure of Interest</h3> None declared
Critical residues in the multidrug resistance 3 protein gene associated with adult onset cholangiopathy and intrahepatic cholestasis of pregnancy.
Authors: S Strautnieks, A Lopes, J Underhill, S Gerred, K Nibbering, A Knisely, B Portman, Adrian Bomford, N Heaton, Giorgina Mieli-Vergani, R Oude-Elferink, J O'Grady, S Wali, Richard Thompson
Journal: Hepatology (2002)
THU0502 Comparison of Low Doses of Systemic Corticosteroids Therapy in Diabetic Patients with Oligoarticular or Polyarticular Gout Flares: An Observational Retrospective Study
Authors: C.A. Guillen-Astete, A. Boteanu, M. Villarejo-Botija
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ACR and EULAR recommendations in management of gout flares with oligoarticular involvement points that systemic corticosteroids should be strongly considered in patients with oligoarticular gout flares. However, some considerations must be taking into account before been used, especially in diabetic patients with an unstable glycemic control of with history of hyperglycaemic states after corticoids administration. Instead of avoiding its use, some clinicians use doses lesser than recommended in such patients with different results. <h3>Objectives</h3> To compare the effectiveness of different doses of corticoids in diabetic patients with acute oligoarticular gout flares fixed to weight and colchicine doses. <h3>Methods</h3> An observational retrospective study was performed. Electronic charts of diabetic patients who consulted to our A&amp;E department from 2013 and 2015 and were diagnosed by oligoarticular gout flare were identified and revised. Registries included patients with oligoarticular gout flares who were not treated with parenteral corticoids or joint infiltrations. They were grouped according to the corticoids dose received fixed by weight and colchicine treatment. Main outcome variables were: need of further consultation before 14th day, VAS-pain score at 7th and 14th day, hyperglucemic states and time off work, where applied. Treatments with systemic corticoids were classified in two arbitrary groups: up to 0.30mg/kg/day (Group I) and 0.31 to 0.49mg/kg/day (Group II). Patients who were treated with higher doses were considered regular doses and were excluded. <h3>Results</h3> During the period of observation, 81 registries of diabetic patients diagnosed by gout flares with more than a joint involved were detected. Among them, only 62 had complete registries of weight (diabetic control at primary care facility) and complete follow up assessment after gout flare. 29 and 32 patients were included in groups I and II, respectively. Table 1, summarizes the results of the study. <h3>Conclusions</h3> In diabetic patients with oligoarticular or polyarticular gout flares the therapeutic approach with prednisone doses higher than 0.3mg/kg/day seems to be associated with a lower tendency of need of new clinical assessment, and a better pain control without a higher frequency of hyperglucemic states. <h3>Disclosure of Interest</h3> None declared
SP0106 Neuropeptides, TRPS and Inflammation: Focus on The Joint
Authors: S. Brain
Journal: Annals of the Rheumatic Diseases (2016)

Arthritis is a debilitating condition characterised by chronic pain in and around the joint. Sensory nerves that contain and release neuropeptides innervate the joint and play a major role in mediating pain. We are interested in the role of the transient receptor potential (TRP) channels, that are calcium-permeable cation channels in mediating the pain and inflammation that occur in the joint during arthritis. We have used TNF and CFA murine models of joint inflammation to elucidate mechanisms. Our early work investigated the role of TRPV1, a channel that is localised to sensory nerves and best known for its activation by the chilli pepper extract capsaicin, noxious heat as well as certain lipids. Studies in TRPV1 knockout mice revealed that CFA thermal pain was alleviated, but TNF levels remained high. TRPA1 is a second TRP channel localised to TPRV1-containing sensory nerves. TRPA1 is activated, amongst other things, by noxious cold and reactive oxygen species. TRPA1 mediates pain in arthritis, as demonstrated by studies including from our laboratory, in a number of species. We have shown that TRPA1 is a vascular cold sensor, also that mice demonstrate exacerbated CFA-induced joint pain after environmental cold exposure. Finally we have now discovered evidence of a regulatory role for the TRPC5 receptor, in that TRPC5KO mice exhibit an enhanced inflammation that is mirrored in WT mice treated with a TRPC5 antagonist. Thus there is compelling evidence that TRP receptors have potential roles in mediating pain, and in some cases the inflammation, in arthritis. They can act via pro-inflammatory and anti-inflammatory mechanisms, depending on subtype. These effects appear to depend on the TRP channels, with some evidence that the neuropeptides are also involved in pain processing. <h3>Disclosure of Interest</h3> None declared
SAT0001 Identification of Sjögren's Syndrome Risk Loci near TNFAIP3 and PRDM1
Authors: C. Lessard, H. Li, J.A. Ice, I. Adrianto, A. Rasmussen, D.M. Lewis, L. Radfar, D.U. Stone, C.G. Montgomery, N.L. Rhodus, R.H. Scofield, A.D. Farris, R. Omdal, M. Wahren-Herlenius, I. Alevizos, T. Witte, R. Jonsson, M. Rischmueller, L. Ronnblom, X. Mariette, W.-F. Ng, G. Nordmark, K.L. Sivils
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sjögren9s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors playing important roles in its etiology. <h3>Objectives</h3> The goal of this study was to replicate 8 suggestive loci that failed to exceed the genome-wide significance (GWS) threshold of 5x10E-8 in our previously published work: <i>TNFAIP3</i>, <i>PTTG1</i>, <i>PRDM1</i>, <i>DGKQ</i>, <i>FCGR2A</i>, <i>IRAK1BP1</i>, <i>ITSN2</i>, and <i>PHIP</i>. <h3>Methods</h3> Our previous study included 1638 SS cases and 6754 population controls. In the current study, we genotyped an additional 282 SS cases and 2576 population controls yielding a total of 1920 SS cases and 9330 controls. Analysis was done using logistic regression accounting for ancestry and gender. <h3>Results</h3> Two regions exceeded the GWS threshold. Association has been previously established with SS to a risk haplotype spanning the <i>TNFAIP3</i> coding region described in lupus; however, we identified a novel independent effect ∼230kb 59 of <i>TNFAIP3</i> (rs6933404 P<sub>meta</sub>=6.85x10E-9, OR=1.28) originally described in rheumatoid arthritis. Association was observed for the haplotype spanning the <i>TNFAIP3</i> coding region peaking at rs58721818 (P=4.77x10E-4), which is not correlated with rs6933404 (<i>r</i><sup>2</sup>=0.02; D9=0.49). Bioinformatics data provided limited support that rs6933404 is the functional variant in this region; however, another variant on this haplotype also surpassing GWS, rs6927172, modifies 8 transcription factor binding sites, and is located within an enhancer element in CD4<sup>+</sup>CD25<sup>–</sup>IL17<sup>+</sup> PMA-Ionomycin stimulated Th17 primary cells by the Epigenetics Road Map Project. A variant in the region of <i>PRDM1</i> also surpassed the GWS threshold (rs526531 P<sub>meta</sub>=1.70x10E-8, OR=1.25). Two additional variants on this haplotype exceeded GWS, but no clear candidate functional variant has emerged based on bioinformatics data. Of the 6 remaining suggestive regions, <i>PTTG1</i>, <i>DGKQ</i>, and <i>FCGR2A</i> continue trending towards GWS. <h3>Conclusions</h3> These data now establish 2 new SS risk loci, <i>TNFAIP3</i> and <i>PRDM1</i>. <i>TNFAIP3</i>, which codes for the protein A20, is a negative regulator of NF-kB. <i>PRDM1</i>, which codes for the protein BLIMP1, is a transcription factor that regulates interferon-beta locus and plasma cell differentiation. Additional studies are needed to determine how these association signals function in the human genome and contribute to SS etiology. <h3>Disclosure of Interest</h3> None declared
OP0105 The Predictors for 12 Months Efficacy of Denosumab, An anti-RANKL Antibody, on Osteoporosis in Patients with Rheumatoid Arthritis from Multicenter Study (TBCR-Bone)
Authors: Y. Hirano, Y. Kanayama, M. Isono, N. Ishiguro, T. Kojima
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although medication of rheumatoid arthritis (RA) has been improved by early intensive treatment using MTX and biological agents (BIO) for decades, treatment of concomitant disease in RA patients, such as osteoporosis (OP), will be more important to improve activity of daily living of RA patients. Although denosumab (DMB), an anti-RANKL antibody, was approved for treatment of OP in Japan in 2013, clinical data in real world is lacking in patients with RA. <h3>Objectives</h3> To investigate the 12 months efficacy of DMB on OP in patients with RA (RA-OP) and predictors of efficacy from multicenter registry study in Japan (TBCR-BONE). <h3>Methods</h3> 64 female cases with RA-OP were included in this study. Bone mineral density (BMD) of lumbar spine (LS-BMD) and total hip (TH-BMD) and bone turnover markers (P1NP and TRACP-5b) were measured at baseline and every 6 months to 12 months. <h3>Results</h3> Mean age was 69 years old. Mean RA duration was 16 years. Mean DAS28-CRP was 2.7. 44% of cases had the past history of fracture. Mean FRAX was 26%. Daily teriparatide was used in 12 cases before DMB treatment. LS-BMD at 6m and 12m was significantly increased compared with baseline (4.3% and 5.9%) (Fig1). TH-BMD at 6m and 12m was significantly increased compared with baseline (3.1% and 4.0%) (Fig1). Mean decrease in P1NP were 39.9% at 6m and 34.3% at 12m. Mean decrease in TRACP-5b were 31.5% at 6m and 27.2% at 12m. Next, all cases were divided into two group, good outcome group (GO group) and non-good outcome group (non-GO group), by mean %increase of LS-BMD and PF-BMD at 12 months. %increase of LS-BMD at 6m in LS-GO group (n=31) was significantly larger than that in LS-non-GO group (n=30) (7.6% vs. 0.9%). Baseline P1NP in LS-GO group was also larger than that in LS-non-GO group (62.5μg/l vs. 45.4μg/l). There were no significant differences in changes of BTMs between two groups. %increase of TH-BMD at 6m in TH-GO group (n=30) was significantly larger than that in TH-non-GO group (n=31) (5.0% vs. 1.2%). There were no significant differences in changes of BTMs between two groups. <h3>Conclusions</h3> DMB was effective in RA-OP. Early response of BMD and baseline P1NP level were suggested to be the predictors of the efficacy of DMB in RA-OP. Higher baseline P1NP and higher LS-BMD increase at 6m were the predictors of better LS-BMD increase at 12m. Higher TH-BMD increase at 6m was the predictors of better LS-BMD increase at 12m. <h3>Disclosure of Interest</h3> None declared
A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,
Authors: Peter M. Voorhees, Robert F Manges, Pieter Sonneveld, Sundar Jagannath, George Somlo, Amrita Krishnan, Suzanne Lentzsch, Richard C Frank, Sonja Zweegman, P.W. Wijermans, Britte Rijnbeek, Xiang Qin, Mark J. Cornfeld, Hong Xie, Sheeba K. Thomas
Journal: Blood (2011)
Prognostic Implications and Biological Roles of RhoH in Acute Myeloid Leukemia.
Authors: Toshihiro Iwasaki, Akira Katsumi, Hitoshi Kiyoi, Ryohei Tanizaki, Miki Kobayashi, Akihiro Abe, Tadashi Matsushita, Tomoki Naoe
Journal: Blood (2007)
THU0512 Insulin Resistance as An Independent Predictor of Subclinical Atherosclerosis in Patients with Gout
Authors: J.H. Kim, H. Jeon, S.H. Kim, H. Kim, J. Yoo, M.K. Chung, J.H. Koh, J. Lee, S.-K. Kwok, J.H. Ju, S.-H. Park
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is linked with metabolic disorders those are important risk factors of cardiovascular diseases. <h3>Objectives</h3> The aim of the present study was to identify independent predictor of subclinical atherosclerosis in patients with gout by measuring presence of atherosclerotic plaque and prevalence of erectile dysfunction (ED). <h3>Methods</h3> We analyzed 80 patients with gout and 70 healthy controls. Carotid plaque and ED were assessed by using ultrasound measurement of carotid plaque and the five-item version of the International Index of Erectile Function questionnaire in participants, respectively. Logistic regression analysis was performed to estimate the effect of variables on presences of carotid plaque or ED on all of the study subjects and patients with gout. <h3>Results</h3> Gout patients had more ED (55.3% vs. 41.4%, p&lt;0.047) and carotid plaque (59.2% vs. 17.1%, p&lt;0.007) compared to controls. After adjustment of compounding factors, only HOMA-IR was significantly associated with ED (OR: 1.82, 95% CI: 1.05–3.15) whereas was not with carotid plaque (OR: 1.02, 95% CI: 0.99–1.47). Gout showed significant association with carotid plaque after multivariate analysis (OR: 13.39, CI: 1.93–92.88). Older age (p&lt;0.001), higher HOMA-IR (p=0.048) and lower GFR (p=0.038) were observed in patients with presence of ED than without ED in gout patients. And gout patients with carotid plaque were older (p=0.003) and had higher insulin level (p=0.035) and HOMA-IR (p=0.039) than without plaque. Logistic regression analysis showed that HOMA-IR was an independent predictor for the presence of both ED (OR: 1.62, 95% CI: 1.03–2.82) and carotid plaque (OR: 1.40, 95% CI: 1.04–1.63). <h3>Conclusions</h3> In our study, insulin resistance was an independent predictor of subclinical atherosclerosis in patients with gout. <h3>Disclosure of Interest</h3> None declared
MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML).
Authors: Ramiro Garzon, Shujun Liu, Muller Fabbri, Zhongfa Liu, Jiuxia Pang, Natarajan Muthusamy, William Blum, Kenneth Chan, John C. Byrd, Carlo M. Croce, Guido Marcucci
Journal: Blood (2007)
PTH-002 Gastrointestinal Bleeding in Dialysis Patients: Identifying Incidence, Risk Factors and Endoscopy Findings: Abstract PTH-002 Table 1
Authors: A Kumar, B Bachi, H Razaq, ED Justice, A Yew, K Shivakumar
Journal: Gut (2016)

<h3>Introduction</h3> Due to the growing incidence of diabetes mellitus and advancing age of patients, there has been a rapid increase in the number of patients on dialysis. These patients are at higher risk of thrombotic complications requiring long term antiplatelet and anticoagulant medications, increasing their risk for bleeding. The most serious source of bleeding is gastrointestinal (GI) bleeding, which accounts for 2.5% of dialysis patients per year. This study was undertaken to determine the incidence and risk factors of GI bleeding in dialysis patients. <h3>Methods</h3> A retrospective study was carried out in a UK district general hospital. Data was collected on all patients that were on haemodialysis and peritoneal dialysis until August 2015. Co-morbidities, medication lists, blood results and endoscopy findings were collated and analysed. <h3>Results</h3> A total of 239 patients were identified to be on dialysis. The incidence of GI bleeds in dialysis patients was 7.9%. The average time from the start of dialysis to the time of bleed was 3 years. The average Hb, platelet count and INR was 68 g/L, 260, and 2.7 respectively. The most common findings on endoscopy included peptic ulcer disease (15.8%), haemorrhoids (15.8%), diverticular disease (15.8%), polyps (10.5%) and normal findings (10.5%). Patients with two or more co-morbidities had a 68% risk of bleeding compared to 54% who had one co-morbidity. Patients on two or more offending medication had a 15.8% risk of bleeding compared to 26.8% who were on single medication therapy. 42% of patients who had a GI bleed required a blood transfusion and 21% needed intervention during endoscopy. See table 1 for full details on risk factors associated with GI bleeding. <h3>Conclusion</h3> There was a higher incidence of GI bleeding in our study as compared with the literature. We identified risk factors as being on anticoagulation, older age, male and having multiple co-morbidities. Being on more than one offending medication or on gastroprotective agents did not suggest higher risk of bleeding. <h3>Disclosure of Interest</h3> None Declared
Poor Prognosis for Patients after Myelo- and Non-Myeloablative Conditioning Therapy Followed by Allogeneic Peripheral Blood Stem Cell Transplantation Admitted to Intensive Care Unit.
Authors: Frank Neumann, Oliver Lobitz, Roland Fenk, Mustafa Kondakci, Thorsten Graef, Ingmar Bruns, Malte Kelm, Ali-Nuri Huenerlituerkoglu, Rainer Haas, Guido Kobbe
Journal: Blood (2006)
Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.
Authors: Bernd Jahrsdorfer, Sue E. Blackwell, James E. Wooldridge, Christiana M. Taylor, George J. Weiner
Journal: Blood (2004)
Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy
Authors: Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter-Brown, Swaminathan Padmanabhan, Andrei Shustov, Jean Nichols, Susan Carroll, John Balser, Steven M Horwitz
Journal: Blood (2010)